Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders November 19, 2020 Auto Bot BioPharma, biopharma nl, Blackstone, blood cancer, FDA, News, Startups 0 The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.